Osteonecrosis Treatment Market Size Report | Size, Share & Forecast 2030

[Research Report] The osteonecrosis treatment market size is expected to grow from US$ 637.18 million in 2022 to US$ 1,021.92 million by 2030; the market is estimated to register a CAGR of 6.08% from 2022 to 2030.

Analyst’s Viewpoint

The osteonecrosis treatment market analysis explains growth drivers such as the rising cases of osteonecrosis in people due to an increasing number of road accidents, and long-term use of steroids among patients. Additionally, an upsurge in the geriatric population and growing awareness about bone health favor the osteonecrosis treatment market progress. However, the high costs of surgical treatments and risks associated with treatment drugs impede the market growth. The adoption of orthobiologics and regenerative therapies is likely to emerge as a future trend in the osteonecrosis treatment market during 2022–2030.

Osteonecrosis, also known as avascular necrosis (AVN), is a painful bone disease caused due to the disruption of blood flow to bones; the condition worsens with time and results in the death of bone cells. The risk factors for osteonecrosis include broken bones, dislocated hips, radiation therapy, and alcohol abuse.

Market Insights

Rising Cases of Orthopedic Injuries and Increasing Geriatric Population Drive Osteonecrosis Treatment Market Growth

According to statistics published by Clevelandclinic.org in 2021, 10,000–20,000 Americans are diagnosed with AVN annually, with the condition affecting individuals of all ages and genders. Nearly ~20% of people who experience hip dislocation develop avascular necrosis. The cases of osteonecrosis are rising globally owing to the increasing number of bone and joint injuries caused during fatal accidents. Although osteonecrosis more commonly affects the hip, it can also hamper the condition of the humerus, knee, and talus. As per an article published by StatPearls in 2023, AVN causes 10% of hip arthroplasties in the US, mostly in people aged 30–65. A displaced hip or knee might cut off blood supply to the leg. As a result, the tissues in the leg may not receive enough blood (a condition known as ischemia) and may die (a condition known as necrosis). Elbow or upper arm fractures can occasionally impede blood flow to the forearm, creating similar complications. When blood supply to a bone is interrupted, a portion of the bone may die, causing osteonecrosis. As per an article published in PubMed Central in January 2022, a cohort study was carried out including 170,934 major trauma patients. The study concluded that 78.0% of the major trauma patients with traumatic hip dislocations were injured in road traffic accidents, particularly in motor vehicle accidents (49.9%).

Older people are more likely to experience osteonecrosis as they are more prone to bone degeneration and fractures. In an article published by PubMed in 2020, a study was carried out to assess the effectiveness of cannulated internal fixation in long-term outcomes in 73 patients with femoral neck fracture (FNF), alongside identifying the risk factors affecting outcomes. The study results showed that out of these, 7 (i.e., ~10%) experienced femoral head necrosis and 4 of them underwent hip replacement. According to World Health Organization (WHO), 1 in 6 people across the world would be aged 60 years or over by 2030, with an estimated 1.4 billion people being over the age of 60. Therefore, the burgeoning geriatric population and growing awareness about bone health favor the osteonecrosis treatment market.  

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Osteonecrosis Treatment Market: Strategic Insights

Osteonecrosis Treatment Market

• 
  CAGR (2022 - 2030)

  6.08%
• Market Size 2022
  US$ 637.18 Million
• Market Size 2030
  US$ 1,021.92 Million

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Zimmer Biomet
• Pfizer Inc
• Stryker
• Exactech Inc
• Merck Co Inc
• Dr Reddy s Laboratories Ltd
• Viatris Inc

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Treatment Type

• Drugs and Surgeries

End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Future Trend

Adoption of Orthobiologics and Regenerative Therapies to Emerge as Future Trend in Osteonecrosis Treatment Market

Orthoregeneration is the segment of medicine that leverages the benefits of biology to enhance healing, reduce pain, improve function, and create a favorable environment for tissue regeneration, thereby curing orthopedic conditions. Interventional orthobiologics, whose functioning is based on the principles of orthoregeneration, are revolutionizing the field of orthopedic medicine. Orthobiologics are derived from a patient's tissues such as bone marrow or blood. They consist of signaling molecules or cells that stimulate the healing of musculoskeletal injuries.

Regenerative treatments such as stem cell therapy, platelet-rich plasma therapy, growth factors, and tissue engineering are being studied and assessed in clinical trials to optimize treatment outcomes. In an article published by PubMed Central in January 2023, a study was carried out to evaluate the use of biologics in treating bilateral AVN of the femoral head in a 44-year-old male suffering from the condition. The patient received bone marrow aspirate concentrate (BMAC) in the right femoral head and adult autologous live cultured osteoblasts in the left femoral head, after which, he was asked to pay follow-up visits for several years. The study concluded that biological therapy using differentiated osteoblasts is a viable option for AVN femoral head compared to an undifferentiated BMAC cocktail.

Key players in the osteonecrosis treatment market are engaged in the R&D of innovative treatments, along with the launch of products. In February 2021, Additive Orthopedics, LLC, received US Food and Drug Administration (FDA) approval for its first patient-specific talus spacer, which is also the world’s first humanitarian-use implant. Similarly, Arthrex, a leading global medical device company, is now offering IntraOsseous BioPlasty (IOBP) technique for spontaneous osteonecrosis of the knee (SONK). This technique involves performing a core decompression of the lesion followed by the direct application of concentrated bone marrow aspirate, which is prepared using the Angel concentrated platelet-rich plasma (cPRP) system.

Report Segmentation and Scope

The “osteonecrosis treatment market” is segmented on the basis of treatment type, end user, and geography. Based on product type, the market is bifurcated into drugs and surgeries. In terms of end user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The osteonecrosis treatment market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America)

Treatment Type – Based Insights

Based on treatment type, the osteonecrosis treatment market is segmented into drugs and surgery. Drug segment held the highest market share in 2020-2030. However, surgeries segment is anticipated to grow with the highest CAGR of 7.63%.

End User-Based Insights

In terms of end user, the osteonecrosis treatment market is categorized into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospitals segment is expected to record the highest CAGR in the market during 2022–2030. Osteonecrosis treatment involves complicated surgeries that need special medical attention, including diagnosis, treatment, and continuous monitoring. Hospitals play an essential role in delivering complete healthcare services to osteonecrosis patients. Depending on the stage and severity of the disease, they provide a variety of treatment options for osteonecrosis. Conservative techniques such as pain management, physical therapy, and lifestyle changes may be included in these treatments. Furthermore, surgical therapies such as joint-preserving operations or joint replacement surgeries may be undertaken in severe cases.

Osteonecrosis Treatment Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Regional Analysis

The osteonecrosis treatment market in North America is expected to grow at a significant rate during the forecast period owing to factors such as the high availability and adoption of advanced treatment options, and the concentration of key manufacturers in the region. The US, in particular, records a high adoption rate of osteonecrosis treatments.

The report profiles important players operating in the global osteonecrosis treatment market. These include Novartis AG; Teva Pharmaceutical Industries Ltd.; Zimmer Biomet; Pfizer Inc.; Stryker; Exactech, Inc.; Merck & Co. Inc.; Dr. Reddy’s Laboratories Ltd.; Viatris Inc; and Horizon Therapeutics plc. These leading players focus on expanding and diversifying their market presence and clientele, thereby tapping business opportunities prevailing in the osteonecrosis treatment market.

A few of the key developments by major market players are as Follows:

• In May 2022, Regrow Biosciences received an Orphan Drug Designation (ODD) for OSSGROW from the USFDA as well as the European Medicines Agency (EMA). The drug is intended for patients who are suffering from osteonecrosis.
• In April 2021, ECI Pharmaceuticals LLC signed an exclusive distribution agreement with AiPing Pharmaceuticals, Inc. The agreement enabled AiPing to handle the sales, marketing, and distribution of ibuprofen 400 mg, 600 mg, 800 mg tablets, and folic Acid 1 mg tablets in the US.
• In February 2021, Additive Orthopaedics received FDA approval for the total talus replacement implant designed as a humanitarian-use device for the talus spacer for the patient-specific treatment of avascular necrosis of the talus in the US.